Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...
Main Authors: | Mohsen, M, Vogel, M, Riether, C, Muller, J, Salatino, S, Ternette, N, Gomes, A, Cabral-Miranda, G, El-Turabi, A, Ruedl, C, Kundig, T, Dermime, S, Knuth, A, Speiser, D, Bachmann, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Frontiers Media
2019
|
Similar Items
-
Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
by: Mohsen, MO, et al.
Published: (2019) -
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.
by: Ruedl, C, et al.
Published: (2005) -
Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.
by: Kündig, T, et al.
Published: (1993) -
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
by: Storni, T, et al.
Published: (2002) -
CTL priming by CD8(+) and CD8(-) dendritic cells in vivo.
by: Ruedl, C, et al.
Published: (1999)